Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 50 Leukemia 15 Gastrointestinal Stromal Tumors 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Leukemia, Myeloid, Chronic-Phase 8 Neoplasms 5 Philadelphia Chromosome 4 Myeloproliferative Disorders 4 Leukemia, Myeloid 4 Bone Marrow Diseases 4 Blast Crisis 4 Hematologic Diseases 3 Hematologic Neoplasms 2 Bronchiolitis Obliterans Syndrome 2 Recurrence 1 Piebaldism 1 Neoplastic Processes 1 Neoplasms by Histologic Type 1 Melanoma 1 Mastocytosis, Systemic 1 Leukemia, Myeloid, Accelerated Phase 1 Hypereosinophilic Syndrome 1 Disease Progression 1

Interventions

pembrolizumab 166 Nivolumab 111 Ipilimumab 93 Dacarbazine 44 trametinib 36 dabrafenib 34 Vemurafenib 33 binimetinib 23 atezolizumab 23 Temozolomide 21 cemiplimab 18 Paclitaxel 18 encorafenib 17 spartalizumab 16 cobimetinib 15 Carboplatin 14 talimogene laherparepvec 13 Cisplatin 13 Cyclophosphamide 12 lenvatinib 10 Pemetrexed 10 Gemcitabine 10 Docetaxel 10 durvalumab 9 Drug Therapy 9 Bevacizumab 9 tremelimumab 8 Injections 8 Albumin-Bound Paclitaxel 8 130-nm albumin-bound paclitaxel 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × nilotinib × Clear all

NCT01028222 2015-12-30

TEAM

Novartis

Phase 2 Completed

55 enrolled 13 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡